>> teva has absolutely nothing to do with it. we are -- immediately after we got this kind of information, and we checked, and teva, again, has nothing to do with this. >> do you -- are you concerned at all that the jackson family may sue teva, because of this issue? >> well, but we -- again, we have nothing to do with it. we are producing it, but as far as we know, what has been found there is not -- that batch that we recalled. >> so you're absolutely certain then that this particular lot that michael jackson may have injested, in fact, was not the lot that was contaminated with the bacteria. >> absolutely. >> okay. all right. we have to leave it there. thank you so much for joining us today. live from tel aviv. we appreciate it. good luck to you. >>> all right. when we come back, what you need to know about this morning's earnings round-up and it's a huge week for big oil. find out how to play that sector right now. >> plus, oil traders are under fire, and the push to ban speculators is now making a comeback. details on the le

we have teva pharmaceuticals, up 2%. also beat the street, reaffirming its guidance, finally, we've got staying with pharma. vivus and celgenn in particular, being called the next biotech large cap, not doing much to move shows shares though. let's go to sharon. >> last year, oil prices were soaring above $140 a barrel. but the commodities regulator in the uk says don't blame the speculators for the oil price volatility that is from the uk financial services authority. on the other hand, in washington, the cftc is paying close attention to the role of speculators an also considering setting position limits on energy markets. they say that they are best positioned to set these position limits and meanwhile the exchanges say no, they are already regulating themselves. the cftc's new chairman gary gensler laying out what the exchanges are already doing and what he sees as position limits that are necessary. he says commodities exchanges already use accountability levels to monitor the size of positions, but position limits

. >> i love tea teva. they're revenue growth was phenomenal. it continues to be phenomenal. we're moving forward more on the generic front. love stock. >> all right. and speaking of phrma names, let's head to some options action. pete najarian, you are seeing activity in mile lan. tell us about it. >> it's another generic name and i think teva is the best out there, and the reason they're out there is they may have an issue in one of their plants. now today the news is maybe the the issues weren't as bad as they once were. all kinds of options are moving out and particularly to september 15th. these are very, very cheap shots and could build off of what we have heard and they are not just a generic company. a phenomenal job and acquiring and looking out in the space. myelin might be a name that would trig or there. back to a.m. jen. the good thing about their drug sale citizen fact that they mentioned the economic recovery that brought spending back. their drugs -- >> have to go to the next trade weighing

names like amgen, for example, teva pharmaceuticals having a good day. amgen better than sfeked earnings, boosted the outlook after the bell today. certainly on the plus side. put all this into context, today a much weaker than expected consumer confidence number. but that was canceled out really by case shiller. maybe the first time that you can really put housing and bottom in the same sentence as that report showed the first rise in home prices month over month in three years. yes, it is that significant. also, general electric, the parent company of this network giving a boost to the market today saying it did not need an additional capital raise for ge capital. that was big news. the dow industrials down about 12 points as we go to the close. here's the bell and maria is going to pick you up. >> and it is 4:00 on wall street. do you know where your money is? welcome to the "closing bell." i'm maria bartiromo on the floor of the new york stock exchange. stocks struggling today on wall street although we are very close to flat as we settle out. the dw

. >> finally and quickly, the other day the ceo of teva told us that watson and mylan would fit into his company's long-term strategy. isn't it just a matter of time before you get bought by teva or maybe a big phrma that wants a bigger footprint in generic drugs? >> i've got to give you a lot of credit, mike. each and every time you have me, you seem to put that little slipper in. mylan is a very strong, probably one of the best-positioned global companies in the world. i think we are set. i think the volumes that we do to become one of the world's global, most efficient low-cost generic pharmaceutical companies, we develop a scale in a commercial platform that is second to none in the industry. and i believe that all of our employees around the world are just absolutely committed for a stand-alone strategy. >> all right. but i'll add that many analysts think this is still a consolidating sector. thanks, robert corey, the ceo of mylan, who, by the way, is ringing the closing bell at the nasdaq today. >> the dow is up 160 points or thereabouts. we've had a lot of good earnings report

has contacted teva about one specific lot of the drug. but the same spokesperson says that that one lot is not part of the two lots that it is voluntarily recalling this week. so read into that what you will. we've got biochris pharmaceuticals up 40% on positive flu drug data. lupus drug data expected out on monday. finally in my beat gilead sciences up 2% on a new deal with j&j on a one a-day hiv/aids drug. of course the big story here, though, is google. and that stock is dragging down the whole internet-related sector with the exception of yahoo, which is up more than 4% right now because oppenheimer raised its price target on yahoo, basically based on a read-through from google's results. and finally we also had a price target raise and an earnings estimate boost out of jpmorgan on apple. that stock's up more than 2.5% ahead of its earnings report coming out next week. for more check out my blog pharmasmarket.cnbc.com, and you can follow me on twitter at mhuckman. >> thank you very much, mike.. i'll take it here at the nymex. want to

and drug administration just sent out an e-mail a few minutes ago saying that the agency as well as teva pharmaceuticals, tick eer t-e-v at the nasdaq are calling the anesthetic drug propofol because they see high endotax i didn't know levels in this drug and the agency says it has received reports of 21 patients who have experienced post operative fever, chills and other flu like symptoms, but goes on to say that serious adverse effects include acute respiratory distress syndrome, shock and death possible with high toxin levels. so it's recalling two lots of this anesthetic, propofol. now, i am making absolutely, absolutely no connection here. but there have been widespread reports over the last couple of weeks or so that this drug may have been found in michael jackson's home, and here we have the fda and teva pharmaceuticals recalling two lots of it because of high endo toxin levels.. >> mike, we've got a news conference going on. sorry to interrupt you. the speaker, madam pelosi is addressing reporters. >> as america's affordable health choices act moves through the legislative proce

if you're going to be in there, i like teva. it's a mixture of generic and proprietary.e in california. george? >> caller: big boo-yah for you, jim. >> boo-yah back. >> caller: i want to know what you think about gdw. >> that's a chinese water company. it is the answer to a lot of people's prayers to try to find some play on water. china is going higher. i am a huge believer in china. i disagree with my friend ron who writes the market movers newsletter. i think it's a buy. i will not embrace this one because i haven't done the homework. how about andrew in new york? >> caller: giddy-up, cramer. andrew from saratoga, new york. >> hey! >> caller: i've got a horse for you. how about aruba networks? we may be clipping heels with -- >> no, no, no. it's part of my mobile internet theory. it's a buy, buy, buy. i think it goes higher. probably get the market down tomorrow. mister softee is going down big because amazon is going down big. it could move your stock lower where i want to buy, buy, buy it. how about ryan in kansas? ryan? >> caller: hey, jim. kansas country boy boo-y

teva is on a tear hitting another new high, up 4%. this company not only beat the veet today but raised earnings guidance for next year saying it's going to have at least 35% organic earnings growth. how many companies can say that in biopharmaceuticals? on the flipside, the company that makes commercial trucks paccar still sees weakness in sales. buffalo wild wings are up 13% or so over the last week, up 6.5% today. the company beat the street today by a buffalo nickel looking ahead to tomorrow, finally, watch shares of onyx farm suitcals, bayer is going to report where sales of the cancer drug they share. let's go to sharon at the nymex. >> mike, when consumer c confidence dips that means there's less demand for energy anna always is a drag on oil prices. we have oil down over $1, and the fact that we got that consumer sentiment figures coming out and that stocks are lower and the dollar a little bit stronger is all weighing on energy prices. we are off of the lows of the session. in the next hour we'll have the report from the ame

we have more earnings in tech, media, barry diller's int interactive, an gwen, and teva pharmaceuticalsxpress scripts. >> let's get back to bulls and bears. peter schiff, a bearish guy, and lee munson, bullish, and mark, bear, john buckingham, bull, and bill sischel, start us off, give us a couple stocks to look at in the coming week. >> it's rich. >> sorry. >> we like materials, overweighted there, dupont, industrials, honeywell is coming out with earnings on monday, could be some positive surprise, they have a nice dividend at 4%, price to earnings ratio relatively low. to tech, intel's numbers were wonderful, microsoft very disappointing. >> second half outlook for intel. and microsoft has a strokng second half outlook. >> intel and microsoft knocked things down and tech needs take a break. we like emt, cisco and ibm and chances to get in cheaper. >> corporate customers have a snap back in demand that has to come into play at some point. lee munson a stock or two. >> one thing we will see in this recovery is a high savings rate along with recovery in the economy. i like amazon, start

on teva, unbelievable results, the acquisition of bar a couple of years ago, phenomenal for them.nd they are going to go out because 70% of their revenue comes from generics, they're going to go out and try and improve that even more. look for them in the m & a space again. >> joe's talked about this one, abbott labs have reported their earnings a week or so ago. they have corrected again the 41.88 low back in april, traded close to 49, the level we talked about for a long time, now pulled back to 45. this 45 level is a 50% correction. play into this all the time. >> go on the attack. >> go on the attack, then, rick, you're half back now at 45. abbott's major drugs don't come off patent until 2017. . >> any trade on the floor in chicago? >> he did. >> irish? >> you can talk about health care without looking at the hmo stocks, hospital stocks, i don't know if people think the obama administration can't keep it together to get significant health care reform, but these things were on fire. i'm a little bit afraid because i think we could see some meaningful legislative change, but my